References
- John J., et al. Acyclovir, an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37: 233–309
- Galle P. R., Theilman L. Inhibition of hepatitis B virus polymerase‐activity of various agents. Arzneim.‐Forsch./Drug Res. 1990; 40(II)1380–1382, Nr. 12
- Mehvar R., Robinson M. A., Reynolds J. M. Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J. Pharm. Sci. 1994; 83: 1495–1499, [PUBMED], [INFOTRIEVE]
- Tu J., Wang L., Yang J., He F., Li X. Formulation and pharmacokinetic studies of acyclovir controlled‐release capsules. Drug Dev. Ind. Pharm. 2001; 27: 687–692, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 2000; 69: 1–25, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kjell M. A., Terence J. P. Periodate oxidation of methyl glycopyranosides: rate coefficients and relative stabilities of intermediate hemiacetals. Carbohydr. Res. 1981; 89: 73–82, [CROSSREF]
- Bailer J. A. Testing for the equality of area under the curves when using destructive measurement techniques. J. Pharmacokinet. Biopharm. 1988; 16: 303–309, [PUBMED], [INFOTRIEVE]